Intuitive Surgical's recurring revenue now accounts for 85% of total revenue, driven by a growing installed base of 11,710 da Vinci systems and an early-stage upgrade cycle to the da Vinci 5 platform. The company reported quarterly instruments and accessories revenue of $1.73 billion, up 18%, while non-GAAP gross margin expanded to 70.0%. With only about 1,700 of nearly 13,000 total systems upgraded and over 100 platform updates planned, the dV5 supercycle is in its early phases. The company holds $8.6 billion in cash and investments against $2.58 billion in total liabilities, and free cash flow reached $1.8 billion in the first half of 2026. Competitors Medtronic's Hugo and Johnson & Johnson's Ottava remain early or pre-commercial, leaving Intuitive Surgical's soft-tissue robotics franchise without direct competition at scale.
